#USA #Boston #Clinical Trials #EMA Wellness #Mira Analytics

EMA Wellness Partners with Mira Analytics

EMA Wellness (EMAW), a leader in clinical trial data platforms focused on AI-enhanced electronic Clinical Outcome Assessments (eCOA), has announced a significant partnership with Mira Analytics. This collaboration aims to utilize state-of-the-art artificial intelligence to validate endpoints in global Central Nervous System (CNS) clinical trials. This strategic alliance marks a pivotal moment in the clinical research sector, where advanced technology promises to enhance both accuracy and efficiency.

The Foundation of the Partnership

EMAW's robust platform standardizes the collection of multimodal data, integrating technologies such as eCOA, audio and video recordings, electronic medication administrations (EMA), digital biomarkers, and passive sensor data. With this comprehensive approach, EMAW has developed a unified architecture that provides real-time analytics and AI-driven signal detection. These advancements not only facilitate real-time clinical trials but also refine study designs and improve subject selection and endpoint reliability. Furthermore, EMAW has successfully validated its platform in many Phase 2 and Phase 3 global trials, ensuring compliance with stringent regulations including HIPAA, GDPR, and 21 CFR part 11.

Mira Analytics brings a wealth of expertise, having developed AI models capable of assessing and independently scoring thousands of recorded clinical interviews in previous CNS trials. Their cutting-edge technology allows for precise rater surveillance, which automatically identifies discrepancies in primary ratings. By doing so, sponsors can enhance consistency and reliability in real-time, enabling superior decision-making regarding participant inclusion, stratification, and remediation during trials.

Unifying Efforts to Drive Quality Assurance

Colin Bower, EMA Wellness's co-founder and CEO, emphasized the importance of transforming high-quality, multimodal clinical data into actionable insights. He stated, “By integrating Mira's models directly into our platform, sponsors can shift from retrospective review to continuous quality assurance across their trials.” This integration is poised to revolutionize how clinical data is managed, thus meeting the growing demands of sponsors and regulatory bodies such as the FDA for real-time data access and proactive signal detection across diverse data modalities.

In response to this partnership, Miguel Pinheiro, co-founder and CTO of Mira, expressed excitement about collaborating with EMAW. He noted, “Their platform will enable us to access the required audio standards and allow us to collaborate with more sponsors to amplify the use of our models in trials.” Bower also acknowledged the longstanding relationship they have built with Mira's founders, stating that their collective efforts have led to meaningful improvements in endpoint quality and substantial returns on investment for their sponsors.

The Role of AI in Transforming Clinical Trials

Clinical interviews have long been considered one of the most information-rich forms of data collected in CNS trials, yet they are notoriously challenging to measure consistently. Adam Kolar, Mira's co-founder and CEO, acknowledged this challenge: “That’s the gap our models are built to close.” This partnership aims to apply precision at scale, expanding across various therapeutic areas and programs.

EMAW boasts an impressive track record, capturing and validating 100% of all clinical interviews while also addressing quality issues across sites and raters. With its AI-driven flagging system, EMAW enables targeted, real-time reviews by clinicians, which can significantly cut down on manual work and costs while improving the quality and consistency of ratings.

The integration of AI into EMAW's platform, known as GIANT™, allows standardization of multimodal data in clinical trials including eCOA, EMA diaries, sensor data, and other real-world data sources. This standardization lays the foundation for AI-enabled real-time analytics and signal detection, which ultimately enhances subject selection, endpoint reliability, and treatment effect phenotype.

Moving Forward

As the clinical trial landscape continues to evolve, EMA Wellness and Mira Analytics are at the forefront of innovation, driving forward to define the future of clinical research. With their joint commitment to integrating AI into trial methodologies, they aim to drastically reduce timelines, costs, and risks associated with drug approvals while improving patient outcomes. Their solutions are currently utilized in over 25 countries and 250 sites, aligned with their mission to further precision in medicine and treatment insights.

In summary, the collaboration between EMA Wellness and Mira Analytics not only promotes a technology-driven approach to clinical trials but also positions both organizations as leaders in the industry, paving the way for enhanced clinical outcomes and efficiencies in the years to come.